Fact Meets Function

Neurodegenerative NMNAT2 Deficiency Promotes APP Processing in a SARM1-Dependent Manner.

This study reveals that NMNAT2 deficiency disrupts NAD+ metabolism and triggers accumulation of toxic APP protein fragments in neurons, driving neurodegenerative pathology through SARM1 activation. The research demonstrates a mechanistic link between metabolic stress (NAD+ depletion) and protein misfolding characteristic of Alzheimer’s disease. Critically, SARM1 knockdown—but not NAD+ supplementation alone—restored metabolic function and normalized pathology, suggesting SARM1 inhibition may be more therapeutic than simple NAD+ replenishment. This repositions NMN and NAD+-boosting strategies in the context of neurodegenerative disease prevention and treatment.

Neurodegenerative NMNAT2 Deficiency Promotes APP Processing in a SARM1-Dependent Manner. Read Post »

Cuproptosis causes meiotic metaphase I arrest by disrupting mitochondrial functions in oocytes.

This research demonstrates that copper-induced cell death (cuproptosis) impairs female oocyte maturation by disrupting mitochondrial function and energy production. The study found that NMN supplementation—a NAD+ precursor—effectively restores mitochondrial function and partially rescues meiotic arrest in oocytes exposed to copper stress. The findings position NAD+ metabolism as a therapeutic target for protecting egg quality and female fertility, with direct clinical implications for practitioners working with reproductive health.

Cuproptosis causes meiotic metaphase I arrest by disrupting mitochondrial functions in oocytes. Read Post »

Nicotinamide Ameliorates Deoxynivalenol-Induced Injury in Renal Cells via Inhibiting PARP1 Hyperactivation and Restoring NAD+ Homeostasis.

This in vitro study demonstrates that the mycotoxin deoxynivalenol (DON) causes severe renal cell damage primarily through PARP1 hyperactivation and consequent NAD+ depletion, rather than through NAMPT inhibition as previously thought. Nicotinamide (NAM) successfully rescued cells by suppressing PARP1 activity and restoring NAD+ pools, while NMN supplementation alone did not protect against DON toxicity. The findings suggest that NAD+ restoration strategies targeting PARP1 inhibition may offer therapeutic value for mycotoxin exposure, relevant to practitioners considering NAD+-supporting interventions for clients with food safety concerns or oxidative stress conditions.

Nicotinamide Ameliorates Deoxynivalenol-Induced Injury in Renal Cells via Inhibiting PARP1 Hyperactivation and Restoring NAD+ Homeostasis. Read Post »

Targeting the Gut-Brain Axis: Protective Effects of NMN in Alleviating D-Galactose-Induced Cognitive Deficits.

This peer-reviewed study demonstrates that NMN, an NAD+ precursor, protects against age-related cognitive decline in mice by reducing oxidative stress, suppressing neuroinflammation, and modulating gut microbiota composition toward butyrate-producing bacteria. The mechanism involves activation of the Nrf2/HO-1 antioxidant pathway and increased antioxidant enzyme activity in the hippocampus. These findings support NMN as a therapeutic strategy for age-related neurodegeneration via gut-brain axis modulation at doses of 300-500 mg/kg.

Targeting the Gut-Brain Axis: Protective Effects of NMN in Alleviating D-Galactose-Induced Cognitive Deficits. Read Post »

Safety of beta-nicotinamide mononucleotide (β-NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC.

The European Food Safety Authority (EFSA) has issued a formal safety opinion approving beta-NMN as a novel food ingredient for use in supplements at up to 300 mg/day for adults (excluding pregnant/lactating women). The Panel confirmed NMN is bioavailable as a source of niacin with a 1:1 conversion factor to nicotinamide, poses no genotoxicity concerns, and is safe based on animal and human data, with the proposed intake remaining well below the 900 mg/day upper safety limit for nicotinamide.

Safety of beta-nicotinamide mononucleotide (β-NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC. Read Post »

Nicotinamide mononucleotide (NMN) improves the ovarian microenvironment associated with oocyte quality by increasing estrogen signaling, reprogramming ovarian metabolism, reducing oxidative stress, and inhibiting apoptosis in the spotted scat (Scatophagus argus).

This animal study in spotted scat fish demonstrated that NMN injections significantly improved ovarian function by increasing NAD+ levels and estrogen production. The treatment enhanced glucose and lipid metabolism, reduced oxidative stress, and improved mitochondrial function in ovarian tissue. Key findings included upregulation of steroidogenesis genes, increased antioxidant capacity, and reduced cellular death pathways, all contributing to better oocyte quality and reproductive health.

Nicotinamide mononucleotide (NMN) improves the ovarian microenvironment associated with oocyte quality by increasing estrogen signaling, reprogramming ovarian metabolism, reducing oxidative stress, and inhibiting apoptosis in the spotted scat (Scatophagus argus). Read Post »

Intracellular NAD+ Depletion Increases Prostanoid Production via p38/COX2 Signalling in FK866-Induced Senescent Human Umbilical Vein Endothelial Cells.

This study demonstrates that NAD+ depletion in vascular endothelial cells triggers a senescence-like state that increases production of pro-inflammatory prostanoids (PGF1α and TXB2) via p38 MAPK and COX2 activation. Using FK866 to deplete NAD+, researchers showed this pathway drives vascular dysfunction associated with aging and cardiovascular disease. Crucially, NMN supplementation reversed NAD+ depletion, suppressed the senescence phenotype, and attenuated prostanoid overproduction, suggesting NAD+ restoration as a therapeutic target for age-related vascular pathology.

Intracellular NAD+ Depletion Increases Prostanoid Production via p38/COX2 Signalling in FK866-Induced Senescent Human Umbilical Vein Endothelial Cells. Read Post »

Anti-inflammatory effects of nicotinamide mononucleotide (NMN) in human skeletal muscle after BFR-exercise.

This human clinical study examined how nicotinamide mononucleotide (NMN) supplementation affected inflammatory markers in skeletal muscle following blood flow restriction (BFR) exercise in humans. The researchers measured inflammatory responses in muscle tissue after participants completed BFR-exercise with and without NMN administration. The findings indicate that NMN supplementation was associated with reduced inflammatory markers in human skeletal muscle post-BFR exercise, though the magnitude and functional significance of these anti-inflammatory effects would require review of the full results.

Anti-inflammatory effects of nicotinamide mononucleotide (NMN) in human skeletal muscle after BFR-exercise. Read Post »

Sirt1-eIF2α axis drives pro-inflammatory macrophage activation through ER stress aggravating liver IRI in aged mice.

This study found that older livers are more prone to damage after transplant surgery due to increased inflammation from immune cells called macrophages. When researchers gave NMN supplements to aged mice, it restored cellular energy levels and reduced this harmful inflammation in the liver. The NMN worked by activating a protein called Sirt1 that helps control inflammatory responses. This suggests NMN could help protect older organs during surgical procedures.

Sirt1-eIF2α axis drives pro-inflammatory macrophage activation through ER stress aggravating liver IRI in aged mice. Read Post »

Nicotinamide mononucleotide supplementation modulates gut microbiota and metabolites to mitigate Alzheimer’s disease pathology in APP/PS1 mice.

This study tested NMN supplementation in mice with Alzheimer’s disease and found it improved both gut health and brain function. NMN restored healthy gut bacteria balance, reduced brain inflammation, and enhanced memory performance in the test animals. The research suggests NMN works through a gut-brain connection, improving the intestinal barrier while also protecting brain cells from damage. These findings indicate NMN may offer a dual approach to supporting both digestive and cognitive health.

Nicotinamide mononucleotide supplementation modulates gut microbiota and metabolites to mitigate Alzheimer’s disease pathology in APP/PS1 mice. Read Post »

Role of nicotinamide adenine dinucleotide in cardiovascular disease.

This review examines NAD+ (nicotinamide adenine dinucleotide) as a critical cellular energy cofactor and its role in cardiovascular health. NAD+ levels naturally decline with age and disease, contributing to cardiovascular dysfunction. The review likely covers how NAD+ supplementation through precursors like NMN may help restore cellular energy metabolism and support heart health. This positions NAD+ enhancement as a therapeutic target for cardiovascular disease prevention and treatment.

Role of nicotinamide adenine dinucleotide in cardiovascular disease. Read Post »

ROS-responsive microneedle patch delivering NMN@Cu/CeO₂ nanozyme for restoring immune microenvironment and mitochondrial homeostasis to potentiate diabetic wound healing.

Researchers developed a specialized microneedle patch that delivers NMN along with nanozymes directly to diabetic wounds. In diabetic mice, this combination significantly improved wound healing by restoring cellular energy metabolism, reducing inflammation, and promoting blood vessel formation. The study demonstrates that targeted NMN delivery can address the underlying metabolic dysfunction that makes diabetic wounds heal poorly. This validates NMN’s therapeutic potential beyond general anti-aging applications.

ROS-responsive microneedle patch delivering NMN@Cu/CeO₂ nanozyme for restoring immune microenvironment and mitochondrial homeostasis to potentiate diabetic wound healing. Read Post »

Shopping Cart
Scroll to Top